Plasminogen activator inhibitor-1 in girls with precocious pubarche: a premenarcheal marker for polycystic ovary syndrome? (Q43865647)

27 November 2017

Plasminogen activator inhibitor-1 in girls with precocious pubarche: a premenarcheal marker for polycystic ovary syndrome? (English)

1 reference

polycystic ovary syndrome

27 November 2017

1 reference

1 reference

5

1 reference

27 November 2017

4

Ken Ong

1 reference

27 November 2017

6

Francis de Zegher

1 reference

27 November 2017

3

Neus Potau

1 reference

27 November 2017

Lourdes Ibáñez

1

1 reference

27 November 2017

Carles Aulesa

series ordinal

2

1 reference

27 November 2017

language of work or name

English

0 references

publication date

1 February 2002

1 reference

27 November 2017

1 reference

27 November 2017

51

1 reference

27 November 2017

2

1 reference

27 November 2017

244-248

1 reference

https://scigraph.springernature.com/pub.10.1203/00006450-200202000-00019

27 November 2017

0 references

cites work

Hyperinsulinemia and decreased insulin-like growth factor-binding protein-1 are common features in prepubertal and pubertal girls with a history of premature pubarche.

1 reference

https://api.crossref.org/works/10.1203%2F00006450-200202000-00019

Hyperinsulinaemia, dyslipaemia and cardiovascular risk in girls with a history of premature pubarche.

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2F00006450-200202000-00019

Anovulation after precocious pubarche: early markers and time course in adolescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2F00006450-200202000-00019

Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2F00006450-200202000-00019

Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2F00006450-200202000-00019

Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2F00006450-200202000-00019

Hyperinsulinemia in polycystic ovary syndrome correlates with increased cardiovascular risk independent of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2F00006450-200202000-00019

Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2F00006450-200202000-00019

Precocious pubarche, hyperinsulinism, and ovarian hyperandrogenism in girls: relation to reduced fetal growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2F00006450-200202000-00019

Precocious pubarche, dyslipidemia, and low IGF binding protein-1 in girls: relation to reduced prenatal growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2F00006450-200202000-00019

Polycystic ovary syndrome after precocious pubarche: ontogeny of the low-birthweight effect.

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2F00006450-200202000-00019

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2F00006450-200202000-00019

Plasminogen-activator inhibitor type 1 and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2F00006450-200202000-00019

Birth weight and the insulin resistance syndrome: association of low birth weight with truncal obesity and raised plasminogen activator inhibitor-1 but not with abdominal obesity or plasma lipid disturbances

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2F00006450-200202000-00019

Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2F00006450-200202000-00019

Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2F00006450-200202000-00019

The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2F00006450-200202000-00019

Circulating levels of factor VII, fibrinogen, and von Willebrand factor and features of insulin resistance in first-degree relatives of patients with NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2F00006450-200202000-00019

Variations in pattern of pubertal changes in girls

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2F00006450-200202000-00019

Normal and almost normal precocious variations in pubertal development premature pubarche and premature thelarche revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2F00006450-200202000-00019

Genotyping Steroid 21-Hydroxylase Deficiency: Hormonal Reference Data*

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2F00006450-200202000-00019

Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2F00006450-200202000-00019

Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2F00006450-200202000-00019

Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2F00006450-200202000-00019

Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2F00006450-200202000-00019

Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2F00006450-200202000-00019

Haemostatic parameters and vascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2F00006450-200202000-00019

The 4G/4G polymorphism of the hypofibrinolytic plasminogen activator inhibitor type 1 gene: an independent risk factor for serious pregnancy complications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2F00006450-200202000-00019

Plasminogen activator inhibitor activity: an independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2F00006450-200202000-00019

Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2F00006450-200202000-00019

Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2F00006450-200202000-00019

Plasminogen Activator Inhibitor Type-1 Synthesis and mRNA Expression in HepG2 Cells Are Regulated by VLDL

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2F00006450-200202000-00019

10.1203/00006450-200202000-00019

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

27 November 2017

0 references

1 reference